You can't like your own messages.

jq1234t

J Q

Joined Feb 20, 2010

jq1234t
@adamfeuerstein ph3 $CLSN HCC; $FOLD Amigal Fabry; $BMRN GLNS MPS IV; $NKTR NKTR118 OIC; $CLVS COL101 mPanC; $ARQL Tivantinib NSCLC interim

May. 22 at 12:03 AM

from Twitter
jq1234t
@adamfeuerstein $PFE's Xalkori data on pediatric ALCL is very interesting. Is it going to be future competitor for $SGEN's Adcetris?

May. 16 at 10:14 PM

from Twitter
jq1234t
$AMLN Said to Attract Interest From Pfizer, AstraZeneca http://t.co/voMuARBr via @BloombergNews

May. 14 at 11:01 PM

from Twitter
jq1234t
AstraZeneca to Acquire $RDEA for $1.26 Billion http://t.co/4bYwGgOc

Apr. 23 at 2:15 AM

from Twitter
jq1234t
@Pelion2001 @adamfeuerstein $ALTH CHMP http://t.co/SOJqPII1

Apr. 20 at 10:23 AM

from Twitter
jq1234t
$SNY $REGN announced ZALTRAP (aflibercept) in mCRC PDUFA Aug 4, failed in ph3 1st line androgen-indep prostate cancer http://t.co/zh8roySt

Apr. 5 at 1:24 AM

from Twitter
jq1234t
@adamfeuerstein $LLY bought Alnara and Avid in 2010 when both of their drugs were under FDA review, and both of them got CRL. Bad buy!

Apr. 4 at 10:09 PM

from Twitter
jq1234t
$IMGN ImmunoGen Announces Positive Results in Trastuzumab Emtansine (T-DM1) EMILIA Phase III Trial - http://t.co/7pdHhtFm

Mar. 30 at 1:27 AM

from Twitter
jq1234t
@JasonCRG @maverickny @3nt Pain: Probably not since pre-chemo should be mostly asymptomatic or minimally symptomatic. $EXEL #cabozantinib

Mar. 12 at 4:51 PM

from Twitter
jq1234t
$REGN Eylea sales in 2011 $24-$25m, 2012 guidance $140-$160m.

Jan. 9 at 7:18 PM

from Twitter
jq1234t
@adamfeuerstein axitinib isn't as important to $PFE as tivozatinib to $AVEO.

Jan. 3 at 9:12 AM

from Twitter
jq1234t
@adamfeuerstein $AVEO Tivozanib in 2nd line RCC vs Nexavar is more significant IMO because Nexavar is mainly used in this setting.

Jan. 3 at 8:44 AM

from Twitter
jq1234t
@adamfeuerstein $AVEO question about whether tivozanib can make dent on Sutent remains. Need to see full data to make judgement.

Jan. 3 at 6:52 AM

from Twitter
jq1234t
$MITI Blinatumomab Produces Durable Responses in Patients with Relapsed Diffuse Large B Cell Lymphoma Patients http://t.co/qkyiInDm

Dec. 11 at 9:02 PM

from Twitter
jq1234t
@LifeSciencesMkt Post approval drop is true almost across board. Thanks to $HGSI, $DNDN. $VRUS doesn't have approval, isn't counter example.

Dec. 8 at 5:30 PM

from Twitter

Follow jq1234t on StockTwits!

Follow investors and traders that match your style and get a personalized stream of news, charts, and ideas.

41 Followers

Trader Profile

Experience: Professional
Assets Traded: Equities, Options

jq1234t

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow jq1234t on StockTwits!

Trader Profile

jq1234t

Add Twitter Connection

Add Facebook Connection

Add LinkedIn Connection

Follow jq1234t on StockTwits!

Trader Profile

Sign in to StockTwits X

Sign in

Sign up using:

Sign in to StockTwits X

Sign up X

Join StockTwits

Sign up using:

Sign up
using:

Sign up
using: